Drug distributor McKesson missed estimates for third-quarter revenue on Wednesday, hurt by less-than-expected sales in its ...

Healthcare distributor and services company McKesson (NYSE:MCK) fell short of the market’s revenue expectations in Q4 CY2024, ...

McKesson Corporation (NYSE: MCK) has released its fiscal 2025 third quarter financial results. Results can be accessed on ...

Welcome to McKesson's third quarter fiscal 2025 earnings conference call. Please be advised that today's conference is being ...

Q3 2025 Management View Revenue for the quarter grew 18% to $95.3B, with adjusted operating profit increasing 16% to $1.5B. CEO Brian Tyler highlighted strong performance across the U.S.

McKesson inked a deal to buy a controlling interest in Prism Vision Holdings, as it also logged higher profit and revenue in its fiscal third quarter. The drug distributor said Wednesday that it ...

Based on our third quarter performance, we are raising and narrowing our guidance range for fiscal 2025 Adjusted Earnings per Diluted Share to $32.55 to $32.95. We are also pleased to announce the ...

Reports Q3 revenue $95.3B, consensus $95.86B. “McKesson (MCK) reported strong third quarter operational results with broad-based Revenue growth ...

Irving-based McKesson (NYSE: MCK) announced on Feb. 4 an agreement to buy an 80% controlling interest in New Providence, New ...

Shares of McKesson Corp. MCK slipped 1.63% to $594.75 Friday, on what proved to be an all-around rough trading session for ...

McKesson said it will acquire an 80% interest in the provider of general ophthalmology and retina management services. PRISM ...

Welcome to McKesson's Third Quarter Fiscal 2025 Earnings Conference Call. Please be advised that today's conference is being recorded. At this time, I'd like to turn the conference over to Rachel ...